By Sabela Ojea
BridgeBio Pharma said it is fully financed to launch its cardiomyopathy treatment Attruby and read out its phase 3 clinical trials, which are fully enrolled.
Shares rose 8.6% to $31.58 in morning trading. The stock has, however, fallen 20% over the past 12 months.
The biotechnology company on Monday said that since the Food and Drug Administration approved Attruby in November, the treatment has been prescribed to 430 patients by 248 physicians.
BridgeBio Pharma also said it expects $105 million in regulatory milestones from acoramidis - sold under the brand name Attruby - approvals in Europe and Japan in the first half of the year, and that it received $500 million upon the FDA's drug acoramidis approval from royalty facility
Overall in the latest quarter, the company had $406 million in cash, BridgeBio Pharma added.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
January 13, 2025 11:46 ET (16:46 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。